Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global Health Ventures has concluded a one month stability test of a male sexual enhancement drug, X-Excite, as required by European regulatory bodies.
Subscribe to our email newsletter
X-Excite is a new formulation of an existing sexual enchancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance, the company said.
X-Excite is presently in clinical development in Europe.
Global Health Ventures has now completed all the requirements to file with the European Regulatory Agency for approval. Once the company files for approval, it will take 30 to 60 days to get approval, following that it will initiate human clinical trials in Europe which will take 2 to 3 months.
Global Health Ventures president and CEO Hassan Salari said that they are very excited with the results of this study and this completes requirements for filing with the European Agency.
"We shall now proceed with the filing in the next few weeks, we already have a lot of interest from big pharmaceutical companies for X-Excite," Salari said.
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route.